文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

危重症患者β-内酰胺类治疗药物监测:权衡挑战与机会评估临床价值

β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
PubMed 文献 · Crit Care Explor · 2022-07-05
一句话结论综述认为对ICU患者全面开展β-内酰胺类TDM尚无证据支持,仅对有过度或不足暴露风险因素者审慎靶向TDM更合理,但需进一步研究。

该综述回顾了危重症患者动态生理、β-内酰胺类剂量反应、病原菌最低抑菌浓度(MIC)对TDM的影响及药代动力学,并汇总现有临床数据。作者对单中心学术医疗中心因脓毒症或脓毒性休克接受β-内酰胺类治疗的患者进行回顾性分析,约三分之一患者β-内酰胺类治疗不足48小时;在超过48小时者中,仅13.7%存在患者特异性因素(肾脏清除增强、液体过负荷、病态肥胖和/或外科引流),提示β-内酰胺类TDM可能获益。作者结论认为,全面β-内酰胺类TDM策略尚无证据支持,因其尚未显示改善患者导向结局;对存在过度或不足暴露风险因素者审慎靶向TDM是更好的方法,但需进一步研究。临床上选择正确抗生素并积极给予治疗指数宽的β-内酰胺类剂量以克服危重症因素,似乎能给危重症患者最佳生存机会。

要点

  • 对单中心学术医疗中心脓毒症或脓毒性休克接受β-内酰胺类治疗患者的回顾性分析中,约三分之一患者β-内酰胺类治疗不足48小时。
  • 在上述超过48小时的患者中,仅13.7%存在患者特异性因素(肾脏清除增强、液体过负荷、病态肥胖和/或外科引流),提示β-内酰胺类TDM可能获益。
  • 作者结论认为,全面β-内酰胺类TDM策略尚无证据支持,因其尚未显示改善患者导向结局。
  • 作者认为,对存在β-内酰胺类过度或不足暴露风险因素者审慎靶向TDM是更好的方法,但需进一步研究。
  • 作者认为,临床上选择正确抗生素并积极给予治疗指数宽的β-内酰胺类剂量以克服危重症因素,似乎能给危重症患者最佳生存机会。

适用人群与场景

  • 因脓毒症或脓毒性休克接受β-内酰胺类抗生素治疗的重症患者(单中心学术医疗中心回顾性分析人群)。

处置流程与药物剂量

  • 作者认为,临床上选择正确抗生素并积极给予治疗指数宽的β-内酰胺类剂量以克服危重症因素,似乎能给危重症患者最佳生存机会。
  • 作者认为,对存在β-内酰胺类过度或不足暴露风险因素(肾脏清除增强、液体过负荷、病态肥胖和/或外科引流)者审慎靶向TDM是更好的方法,但需进一步研究。

研究设计与关键结果

  • 综述类型:合成性、非系统性综述,结合单中心学术医疗中心脓毒症或脓毒性休克接受β-内酰胺类治疗患者的回顾性分析。
  • 回顾性分析中,约三分之一患者接受β-内酰胺类治疗不足48小时。
  • 在超过48小时继续治疗的患者中,仅13.7%存在患者特异性因素(肾脏清除增强、液体过负荷、病态肥胖和/或外科引流),提示β-内酰胺类TDM可能获益。
  • 作者结论认为,全面β-内酰胺类TDM策略尚无证据支持,因其尚未显示改善患者导向结局。
  • 作者认为,ICU中β-内酰胺类TDM虽值得称赞,但在动态、不可预测的患者人群中,将模糊的β-内酰胺类暴露阈值叠加于不确定/未知的MIC数据上,且TDM结果无法足够快获得以显著影响治疗。

证据类型、等级与局限

  • 证据类型:合成性、非系统性综述,结合单中心回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,全面β-内酰胺类TDM策略尚无证据支持,因其尚未显示改善患者导向结局。
  • 作者认为,对存在β-内酰胺类过度或不足暴露风险因素(肾脏清除增强、液体过负荷、病态肥胖和/或外科引流)者审慎靶向TDM是更好的方法,但需进一步研究。
  • 作者认为,临床上选择正确抗生素并积极给予治疗指数宽的β-内酰胺类剂量以克服危重症因素,似乎能给危重症患者最佳生存机会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: β-lactams are the cornerstone of empiric and targeted antibiotic therapy for critically ill patients. Recently, there have been calls to use β-lactam therapeutic drug monitoring (TDM) within 24-48 hours after the initiation of therapy in critically ill patients. In this article, we review the dynamic physiology of critically ill patients, β-lactam dose response in critically ill patients, the impact of pathogen minimum inhibitory concentration (MIC) on β-lactam TDM, and pharmacokinetics in critically ill patients. Additionally, we highlight available clinical data to better inform β-lactam TDM for critically ill patients.

DATA SOURCES: We retrospectively analyzed patients admitted for sepsis or septic shock at a single academic medical center who were treated with β-lactam antibiotics.

STUDY SELECTION: Indexed studies in PubMed in English language were selected for review on topics relative to critical care physiology, β-lactams, pharmacokinetics/pharmacodynamics, TDM, and antibiotic susceptibility.

DATA EXTRACTION: We reviewed potentially related studies on β-lactams and TDM and summarized their design, patients, and results. This is a synthetic, nonsystematic, review.

DATA SYNTHESIS: In the retrospective analysis of patients treated with β-lactam antibiotics, approximately one-third of patients received less than 48 hours of β-lactam therapy. Of those who continued beyond 48 hours, only 13.7% had patient-specific factors (augmented renal clearance, fluid overload, morbid obesity, and/or surgical drain), suggesting a potential benefit of β-lactam TDM.

CONCLUSIONS: These data indicate that a strategy of comprehensive β-lactam TDM for critically ill patients is unwarranted as it has not been shown yet to improve patient-oriented outcomes. This review demonstrates that β-lactam TDM in the ICU, while laudable, layers ambiguous β-lactam exposure thresholds upon uncertain/unknown MIC data within a dynamic, unpredictable patient population for whom TDM results will not be available fast enough to significantly affect care. Judicious, targeted TDM for those with risk factors for β-lactam over- or underexposure is a better approach but requires further study. Clinically, choosing the correct antibiotic and dosing β-lactams aggressively, which have a wide therapeutic index, to overcome critical illness factors appears to give critically ill patients the best likelihood of survival.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Dilworth TJ, Schulz LT, Micek ST, et al. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. Crit Care Explor. 2022. PMID: 35815181. doi:10.1097/CCE.0000000000000726

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。